Imetelstat - Geron Corporation/Janssen Biotech

Drug Profile

Imetelstat - Geron Corporation/Janssen Biotech

Alternative Names: GRN 140719; GRN 163; GRN 163-L; GRN 719; GRN163L peptide; Imetelstat sodium; JNJ-63935937

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Geron Corporation
  • Developer Geron Corporation; Janssen Biotech
  • Class Antineoplastics; Oligonucleotides; Oligopeptides
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myelodysplastic syndromes
  • Phase II Myelofibrosis
  • Preclinical Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Suspended Multiple myeloma
  • Discontinued Breast cancer; Essential thrombocythaemia; Lymphoproliferative disorders; Non-small cell lung cancer; Polycythaemia vera; Solid tumours

Most Recent Events

  • 31 Jul 2018 Following completion of the protocol-specified primary analysis of the IMbark trial, Geron expects Janssen to inform its decision whether it elects to maintain the license rights and continue the development of imetelstat in any indication (the Continuation Decision) by the end of the 3Q 2018
  • 24 May 2018 Janssen completes a phase II trial for Myelofibrosis in USA (NCT01731951)
  • 19 Mar 2018 Janssen completes enrolment in a phase-II clinical trial for Myelofibrosis in USA, United Kingdom, Belgium, France, Germany, Spain, Taiwan, Canada, Israel, South Korea and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top